Skip to the page

Data / Drug companies / Novocol Pharmaceutical of Canada, Inc.

Novocol Pharmaceutical of Canada, Inc.: 12 products in the FDA NDC directory, labeler code 51004

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Novocol Pharmaceutical of Canada, Inc. (labeler code 51004) lists 12 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 11 prescription drugs, 1 drugs for further processing. Its main marketing category is authorized generics (NDA). The newest product started marketing on January 8, 2020.

The request: Watch Novocol Pharmaceutical of Canada, Inc. (FDA labeler code 51004): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
51004
Products in commercial distribution
12
Packages
12
Finished drugs by generic name
4
Prescription products
11
Over the counter products
0
Flagged as original packager
11 of 11 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
October 10, 1984
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Authorized generics (NDA)758.3%
Generic drugs (ANDA)433.3%
Export only18.3%

Products by type

TypeProductsShare
Prescription drugs1191.7%
Drugs for further processing18.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution12100%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Epinephrine injection51004-2400Injection, solutionExport onlyJanuary 8, 2020
Lidocaine51004-2105Injection, solutionGeneric drugs (ANDA)March 18, 2019
Citanest Forte DENTAL51004-5801Injection, solutionGeneric drugs (ANDA)December 4, 2017
Articaine51004-4185Injection, solutionAuthorized generics (NDA)April 4, 2016
Articaine51004-4175Injection, solutionAuthorized generics (NDA)April 4, 2016
Articaine51004-0102Injection, solutionAuthorized generics (NDA)December 4, 2015
Articaine51004-1010Injection, solutionAuthorized generics (NDA)June 22, 2015
Mepivacaine51004-0005Injection, solutionGeneric drugs (ANDA)April 10, 2015
Articaine Hydrochloride and Epinephrine51004-6620Injection, solutionAuthorized generics (NDA)January 28, 2015
Articaine51004-1040Injection, solutionAuthorized generics (NDA)December 22, 2014
Articaine Hydrochloride and Epinephrine51004-6625Injection, solutionAuthorized generics (NDA)January 28, 2014
Polocaine51004-4411Injection, solutionGeneric drugs (ANDA)October 10, 1984

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.